版本:
中国

BRIEF-Bristol-Myers Squibb, Calithera Biosciences expand collaboration

May 10 Bristol-myers Squibb Co

* Bristol-Myers Squibb and Calithera Biosciences expand collaboration evaluating opdivo (nivolumab) in combination with CB-839 into non-small cell lung cancer and melanoma

* Calithera Biosciences Inc - study to evaluate potential of CB-839 plus opdivo to target immunosuppressive cancer metabolism in tumor microenvironment Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐